<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181210041914N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-30</date_registration>
      <primary_sponsor>Bu-Ali Sina University of Hamedan</primary_sponsor>
      <public_title>The effect of lateral wedge sock insoles on the gait of patients with knee arthritis</public_title>
      <acronym></acronym>
      <scientific_title>Biomechanical analysis of the gait of patients with knee osteoarthritis before and after the acute use of the lateral wedge sock insoles</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69762</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, we will use the restricted randomization method of block randomization to balance the number of samples assigned to each group. Specifically, we will form 6 blocks of equal size, each containing 3 participants (3 in the intervention group and 3 in the control group). To generate the random sequence, we will use a software called Random Allocation Software, which can perform both simple randomization and blocking. We will also use concealment allocation to ensure that the assigned group of each participant remains unknown until the moment of assignment. To achieve this, we will use opaque sealed envelopes containing a sequentially numbered random sequence generated on a registration card. The cards themselves will be placed in letter envelopes in order. In order to maintain the randomized sequence, the outer surface of the envelopes will be numbered in the same order. Finally, we will glue the lid of each envelope and place them in a box. When we begin registering participants, we will open an envelope based on the order of entry of eligible participants into the study, revealing the assigned group for that participant, Blinding description: In this study, 60 patients will participate, who will be randomly divided into two control and experimental groups (according to the explanation in the previous section). The intervention group will receive a 6-degree lateral wedge sock insole and the control group will receive a 0-degree neutral insole as a placebo. The insoles will be provided to the participants by the clinical supervisor. Neither the participants nor the researchers and the members of the analysis and evaluation team will know which group received the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Medial Compartment Knee Osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Using the lateral wedge sock insoles; The insole used in this study is designed as a sock for easy use at home without the need for shoes or sandals. As previous research has shown that the 6-degree insole is most effective in reducing pain and improving performance in patients, A 6-degree lateral wedge was selected. The stiffness of the sole will vary from hard on the lateral edge to softer on the medial side. The lateral part will be made of Plastazote foam with a hardness of A: 70, while the medial part will be made of Ethylene-vinyl acetate (EVA) with a hardness of A: 20. The insole supports both the internal longitudinal arch and the transverse arch of the foot to maximize patient comfort. Additionally, a subtalar strap will be used to prevent eversion behind the heel. The upper part of the insole will be made of soft material to ensure patient comfort. The affected foot will use a 6-degree lateral wedge insole, while a 0-degree neutral insole will be used for healthy feet to prevent leg length discrepancy. Intervention 2: Control group: For the control group, a zero-degree neutral insole will be used as a placebo.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is This file is confidential.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereshteh Sabet</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hamedan, Chaharbagh Shahid Mostafa Ahmadi Roshan, Bo Ali Sina University</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517833131</zip>
        <telephone>+98 41 4225 0314</telephone>
        <email>fereshteh_sabet@yahoo.com</email>
        <affiliation>Bu-Ali Sina university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fershteh Sabet</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hamedan, Chaharbagh Shahid Mostafa Ahmadi Roshan, Bu Ali Sina University</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517833131</zip>
        <telephone>+98 41 4225 0314</telephone>
        <email>fereshteh_sabet@yahoo.com</email>
        <affiliation>Bu-Ali Sina University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age range of 40 to 65 years
having radiological signs of mild to moderate osteoarthritis in the knee
chronic knee pain for 1 month or more
morning stiffness for less than 30 minutes
Crepitus</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The presence of any pain or lesion in the lower limb (except knee osteoarthritis)
Use of stimulants, drugs and alcohol
History of neurological and muscle diseases
The presence of any systemic disease such as rheumatism
Diabetes or a history of cardiovascular and pulmonary diseases
History of any surgery in the affected knee
Intra-articular injection (PRP) within the last six months
History of fractures and dislocations in the lower limb during the past year
Having a regular exercise program in the last six months
Having pain less than one day per month
Inability to walk without assistance</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Using the lateral wedge sock insoles; The insole used in this study is designed as a sock for easy use at home without the need for shoes or sandals. As previous research has shown that the 6-degree insole is most effective in reducing pain and improving performance in patients, A 6-degree lateral wedge was selected. The stiffness of the sole will vary from hard on the lateral edge to softer on the medial side. The lateral part will be made of Plastazote foam with a hardness of A: 70, while the medial part will be made of Ethylene-vinyl acetate (EVA) with a hardness of A: 20. The insole supports both the internal longitudinal arch and the transverse arch of the foot to maximize patient comfort. Additionally, a subtalar strap will be used to prevent eversion behind the heel. The upper part of the insole will be made of soft material to ensure patient comfort. The affected foot will use a 6-degree lateral wedge insole, while a 0-degree neutral insole will be used for healthy feet to prevent leg length discrepancy.</i_keyword>
      <i_keyword>Control group: For the control group, a zero-degree neutral insole will be used as a placebo.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee OA Symptoms. Timepoint: Before and after the immediate use of the lateral wedge sock insoles. Method of measurement: WOMAC Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Knee External Adduction Moment (EKAM). Timepoint: Before and after the immediate use of the lateral wedge sock insoles. Method of measurement: Through kinematic data obtained from motion analysis system and kinetic data obtained from the force plate.</sec_outcome>
      <sec_outcome>Coordination and variability of the coordinated pattern of hindfoot and the leg. Timepoint: Before and after the immediate use of the lateral wedge sock insoles. Method of measurement: Through kinematic data obtained from motion analysis System.</sec_outcome>
      <sec_outcome>Center of Pressure (CoP) Path. Timepoint: Before and after the immediate use of the lateral wedge sock insoles. Method of measurement: Using the data obtained from the foot scanner (Foot pressure).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bu-Ali Sina University of Hamedan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-06</approval_date>
        <contact_name>Research Ethics Committee of BU-Ali Sina University, Hamedan</contact_name>
        <contact_address>Bu-Ali Sina University, Shahid Mostafa Ahmadi Roshan Street Hamedan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
